The upregulation of glial glutamate transporter-1 participates in the induction of brain ischemic tolerance in rats.

Glial glutamate transporter-1 (GLT-1) plays an essential role in removing glutamate from the extracellular space and maintaining the glutamate below neurotoxic level in the brain. To explore whether GLT-1 plays a role in the acquisition of brain ischemic tolerance (BIT) induced by cerebral ischemic preconditioning (CIP), the present study was undertaken to observe in vivo changes in the expression of GLT-1 and glial fibrillary acidic protein (GFAP) in the CA1 hippocampus during the induction of BIT, and the effect of dihydrokainate (DHK), an inhibitor of GLT-1, on the acquisition of BIT in rats. Immunohistochemistry for GFAP showed that the processes of astrocytes were prolonged after a CIP 2 days before the lethal ischemic insult, which could protect pyramidal neurons in the CA1 hippocampus against delayed neuronal death induced normally by lethal ischemic insult. The prolonged processes extended into the area between the pyramidal neurons and tightly surrounded them. These changes made the pyramidal layer look like a 'shape grid'. Simultaneously, the prolonged and extended processes showed a great deal of GLT-1. Western blotting analysis showed significant upregulation of GLT-1 expression after the CIP, especially when it was administered 2 days before the subsequent lethal ischemic insult. Neuropathological evaluation by thionin staining showed that DHK dose-dependently blocked the protective role of CIP against delayed neuronal death induced normally by lethal brain ischemia. It might be concluded that the surrounding of pyramidal neurons by astrocytes and upregulation of GLT-1 induced by CIP played an important role in the acquisition of the BIT induced by CIP.     

Fas和mdr-1在急性白血病的表达及其相关性研究

本研究应用流式细胞仪 (FCM)直接免疫荧光法和半定量RT PCR方法分别测定 5 9例初发急性白血病(AL)患者治疗前及完全缓解 (completeremission ,CR)后骨髓Fas和mdr 1mRNA表达情况 ,旨在探讨Fas和mdr 1在AL的表达及二者在多药耐药 (multidrugresistance ,MDR)中的相关性。结果显示 :Fas在初发AML阳性表达率比ALL高 ,两表达率间有差异 (P <0 .0 5 ) ,mdr 1在AML和ALL阳性表达率间无差异 (P >0 .0 5 ) ,Fas 与mdr 1 有负相关性 (r =- 0 .2 82 ,P <0 .0 5 ) ;经单因素及多因素COX分析 ,Fas和mdr 1独立于其他参数 ,更具判断预后价值 ;在Fas 与Fas-的AML和AL ,CR率均有显著性差异 (P <0 .0 1) ,在mdr 1 、mdr 1-的AML和AL中的CR率有显著性差异 (P <0 .0 1) ;经Logrank检验 ,Fas 与Fas-组CR率及中数缓解时间有显著性差异 (χ2 =7.35 ,P =0 .0 0 6 7) ,mdr 1 与mdr 1-组CR率及中数缓解时间有显著性差异 (χ2 =10 .71,P =0 .0 0 11)。结论 :Fas、mdr 1与疗效高度相关 ;Fas阳性表达可能是AL预后良好因素 ;mdr 1为疗效差、预后不良的重要因素。     

老年人与青年人皮肤血流量比较研究

目的 判定增龄对皮肤血流量的影响。方法 用PIM2-LDPI检测皮肤血流量。结果 老年组前额、左手指背、命门穴部位皮肤血流量分别为:(1.94±0.86)V,(1.92±0.52)V和(0.71±0.19)V,与青年组比较差异无显著性。但是,老年男性在命门穴的皮肤血流量明显高于青年男性(P<0.05),老年女性前额的皮肤血流量明显降低(P<0.01)。男性比女性的皮肤血流量高。结论 皮肤血流量的差异无年龄相关性,男性组的皮肤血流量比女性组高。     

互叶醉鱼草中的环烯醚萜甙

从互叶醉鱼草地上部分分出３个环烯醚萜甙粉化合物。经化学和光谱方法测定结构为６－Ｏｃｉｎｎａｍｏｙｌｃａｔａｌｐｏｌ（Ｉ），ｓｐｅｃｉｏｓｉｄｅ（Ⅱ）和６－Ｏ－ｃｉｓ－ｐ－ｃｏｕｍａｒｏｙｌｃａｔａｌｐｏｌ（Ⅲ）。其中化合物Ⅲ为首次从自然界发现。     

64层螺旋CT诊断先天性冠状动脉起源异常的价值

目的：探讨64层螺旋CT冠状动脉造影诊断冠状动脉起源异常的临床价值。材料和方法：回顾性总结2005年12月至2006年12月间1800例64层螺旋CT冠脉造影的结果，统计冠状动脉起源异常的发生率。结果：1800例检查者中发现冠脉起源异常51例，发病率2．8％。包括右冠状动脉变异11例（21．6％）、左冠状动脉变异8例（15．7％）、左右冠均发生变异1例（2％）、单支冠状动脉1例（2％）、分支变异28例（54．9％）。结论：64层螺旋CT是诊断冠状动脉起源异常的安全有效方法，对临床治疗有重要的意义。     

松解及眼轮匝肌下脂肪垫转移充填矫正重睑术后睑粘连畸形

目的矫正重睑成形术后的上睑粘连、重睑较宽、眼睑上抬受限等畸形。方法另设计重睑线,彻底松解眼睑内的组织粘连,释放眶隔内脂肪及转移眼轮匝肌下脂肪垫充填。结果两年来为32例重睑成形术后畸形者用此法治疗得到满意效果。结论此方法简单易行,效果好。     

Foley尿管气囊压迫治疗骶前静脉丛大出血的评价(附6例报告)

目的:评价直肠癌根治术中用Foley尿管气囊压迫治疗骶前静脉丛大出血(MPVP)的临床价值。方法:分析1995~2005年用Foley尿管气囊压迫治疗骶前静脉丛大出血6例的临床资料。结果:6例骶前大出血中全部用Foley尿管气囊压迫控制出血,术中出血量为800~1700mL,Foley尿管于术后4d拔除3例,5d1例,6d2例,均无再出血,会阴切口均一期愈合。结论:Foley尿管气囊压迫治疗骶前静脉丛大出血是一种简单安全有效的治疗方法。     

5株SARS-CoV部分基因序列比较分析

目的　分析SARS CoV部分结构区的基因序列 ,了解其变异程度。方法　采用套式PCR法扩增各结构区基因 ,对阳性PCR产物进行克隆和测序 ,并对序列进行分析。结果　完成了LC1株病毒的M、N、E和S基因的扩增和克隆 ,对LC2、LC3、LC4和LC5株病毒的M区基因进行了扩增和克隆。序列分析显示各结构基因的核苷酸序列与已报道的 18株序列的同源性在 99%以上。结论SARS CoV的基因序列较保守 ,有利于PCR诊断试剂和预防用疫苗的研制。     

The impact of obesity on female reproductive function

Obesity may be described as the new worldwide epidemic, and its serious impact on morbidity and mortality are well known. As more and more women become obese, the reproductive problems associated with obesity present an ever-growing challenge to physicians involved in their fertility care. The spectrum of reproductive problems associated with obesity encompasses a wide range of disorders including infertility problems, miscarriage and pregnancy complications. In this review, we aim to discuss the impact of obesity on the various aspects of female reproductive function with focus on the clinical aspects of fertility problems in obese women. We finally comment on the available therapeutic options available to this group of women.